Get notified when INO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt exists as to its ability to continue as a going concern, with insufficient working capital to fund operations for the next twelve months.
- Litigation (new) — A securities class action and three derivative suits allege materially false and misleading statements regarding the INO-3107 BLA submission and FDA review timeline.
INOVIO prices $18.3M net offering of 21.05M shares plus warrants at $0.95 per unit
Filed July 30, 2026 · ~2 min read
Key Changes
-
high
INOVIO is offering 21,052,632 shares of common stock, each paired with a warrant to buy two additional shares, at a combined price of $0.95 per unit.
The Offering verify on EDGAR → -
high
Net proceeds to the company are approximately $18.3 million, after underwriting discounts and estimated expenses.
Use of Proceeds verify on EDGAR → -
high
The company plans to use net proceeds primarily for preparing a potential commercial launch of INO-3107, conducting a confirmatory trial if required, developing its clinical pipeline, and general corporate purposes.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade INO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify